SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001819790-23-000043
Filing Date
2023-06-21
Accepted
2023-06-21 18:18:45
Documents
3
Period of Report
2023-06-16

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1687385913.html 4  
1 FORM 4 wk-form4_1687385913.xml 4 5792
2 EX-24 a2023-06x10secxpoaandrew.htm EX-24 644
3 a2023-06x10secxpoaandrew001.jpg GRAPHIC 199001
  Complete submission text file 0001819790-23-000043.txt   281981
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618
Business Address
Goldberg Andrew D. (Reporting) CIK: 0001827722 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39614 | Film No.: 231031083